Showing 1071-1080 of 1781 results for "".
- Significant Link Found Between Heme Iron, Found in Red Meat and Other Animal Products, and Type 2 Diabetes Riskhttps://reachmd.com/news/significant-link-found-between-heme-iron-found-in-red-meat-and-other-animal-products-and-type-2-diabetes-risk/2467779/Key points: Researchers identified a significant link between heme iron—iron found in red meat and other animal products —and risk of type 2 diabetes (T2D), as well as the metabolic pathways underlying the link.
- Pandemic Fatigue and Vaccine Hesitancy Continue to Affect Global Public Health, New 23-Country Study in Nature Medicine Reportshttps://reachmd.com/news/pandemic-fatigue-and-vaccine-hesitancy-continue-to-affect-global-public-health-new-23-country-study-in-nature-medicine-reports/2462901/Responses from 23,000 people point to need for more locally relevant communication strategies to increase vaccine confidenceNEW YORK, April 29, 2024 /PRNewswire/ -- While it found that global uptake of at least one COVID
- UAB Researchers Part of GRADE Study Investigating Glucose Medications in Type 2 Diabeteshttps://reachmd.com/news/uab-researchers-part-of-grade-study-investigating-glucose-medications-in-type-2-diabetes/2462495/UAB researchers say the presented data indicates that a younger age and higher HbA1c at baseline predict early treatment failure and point to the need for more aggressive initial treatment in these patients. U
- Urolithin A as a Potential Agent for Prevention of Age-Related Disease: A Scoping Reviewhttps://reachmd.com/news/urolithin-a-as-a-potential-agent-for-prevention-of-age-related-disease-a-scoping-review/2457379/The aging of an organism is hallmarked by systemic loss of functional tissue, resulting in increased fragility and eventual development of age-related neurodegenerative, musculoskeletal, cardiovascular, and neoplastic diseases. Growing scientific evidence points to mitochondrial dys
- Skin Cancer Champions Launches New Sitehttps://reachmd.com/news/Skin-Cancer-Champions-Launches-New-Site/2475125/Skin Cancer Champions announced the launch of a new website, skincancerchampions.org, aimed at making it easier for patients to find what they need, engage with resources, and help more people discover the community. “Our new site is a step forward in making our community more accessible,
- Nonsurgical vs Surgical ACL Care: Knee Function and Return to Sporthttps://reachmd.com/news/nonsurgical-vs-surgical-acl-care-knee-function-and-return-to-sport/2487599/Key Takeaways No statistically significant between-group difference appeared in IKDC-SKF at any measured time point, and scores improved over time in both groups. Seventy-five percent of the cohort returned to sport within 24 months, with similar 24-mo
- C1q Inhibitor Tanruprubart Shows Functional Benefit in Guillain-Barré Syndromehttps://reachmd.com/news/c1q-inhibitor-tanruprubart-shows-functional-benefit-in-guillain-barre-syndrome/2487601/KEY TAKEAWAYS Tanruprubart improved functional recovery in Guillain-Barré syndrome, meeting the primary end point of a phase 3 trial. Earlier treatment after symptom onset and lower baseline neurofilament light levels were associated with great
- Real-World Personalized SLIT Outcomes in Telemedicine Carehttps://reachmd.com/news/real-world-personalized-slit-outcomes-in-telemedicine-care/2487489/Key Takeaways The proportion reaching a 30-point or greater symptom improvement at least once increased from 28% at 12 months to 45% at 24 months. Medication use decreased over time, and more than 80% reported quality-of-life improvement across interva
- Elinzanetant Eases Vasomotor Symptoms In Breast Cancer Trialhttps://reachmd.com/news/elinzanetant-eases-vasomotor-symptoms-in-breast-cancer-trial/2487403/Key Takeaways Larger reductions in symptom frequency than placebo were observed at both prespecified primary time points, weeks 4 and 12. The randomized phase 3 trial enrolled women 18 to 70 years old and used 2:1 assignment to elinzanetant or placebo
- Brepocitinib Phase 3 Trial Findings in Dermatomyositishttps://reachmd.com/news/brepocitinib-dermatomyositis-trial/2487352/Key Takeaways Brepocitinib 30 mg was associated with a higher week-52 Total Improvement Score than placebo in adults with dermatomyositis. The 30-mg dose was also superior across all nine key secondary end points, with improvement observed by week 4.</